Literature DB >> 12122518

Clinical implications of antibiotic-induced endotoxin release in septic shock.

P M Lepper1, T K Held, E M Schneider, E Bölke, H Gerlach, M Trautmann.   

Abstract

Antibiotic-induced release of bacterial cell wall components can have immediate adverse effects for the patient. This article reviews the data on endotoxin release after initiation of antibiotic therapy and its role in the pathogenesis of sepsis and septic shock. Antibiotics differ in their potential to liberate endotoxins from bacterial cell walls. When used for treatment of systemic Gram-negative infection, some classes of beta-lactam antibiotics lead to markedly increased levels of free endotoxins while treatment with carbapenems and aminoglycosides produces relatively low amounts of endotoxins. Antibiotics that induce the formation of long, aberrant bacterial cells before effectively killing the microorganisms show the highest degree of endotoxin liberation. There is increasing evidence from animal models and clinical studies of sepsis that the antibiotic-mediated release of biologically active cell wall components derived from Gram-positive, Gram-negative or fungal organisms is associated with a rapid clinical deterioration.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12122518     DOI: 10.1007/s00134-002-1330-6

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  45 in total

Review 1.  [Endotoxins. Pathogenetic meaning of sepsis].

Authors:  H Rensing
Journal:  Anaesthesist       Date:  2003-12       Impact factor: 1.041

2.  Effect of empiric antibiotic treatment on plasma endotoxin activity in septic patients.

Authors:  F Mignon; M Piagnerelli; M Van Nuffelen; J L Vincent
Journal:  Infection       Date:  2014-01-28       Impact factor: 3.553

3.  Synergistic antibiotic effect of looped antimicrobial peptide CLP-19 with bactericidal and bacteriostatic agents.

Authors:  Di Li; Ya Yang; Zhiqiang Tian; Jun Lv; Fengjun Sun; Qian Wang; Yao Liu; Peiyuan Xia
Journal:  Oncotarget       Date:  2017-05-23

4.  Interception of the endotoxin-induced arterial hyporeactivity to vasoconstrictors.

Authors:  Shuang Zhang; Ningren Cui; Shanshan Li; Lei Guo; Yang Wu; Daling Zhu; Chun Jiang
Journal:  Vascul Pharmacol       Date:  2014-04-30       Impact factor: 5.773

Review 5.  The Impact of Timing of Antibiotics on Outcomes in Severe Sepsis and Septic Shock: A Systematic Review and Meta-Analysis.

Authors:  Sarah A Sterling; W Ryan Miller; Jason Pryor; Michael A Puskarich; Alan E Jones
Journal:  Crit Care Med       Date:  2015-09       Impact factor: 7.598

6.  A purified capsular polysaccharide markedly inhibits inflammatory response during endotoxic shock.

Authors:  M Piccioni; C Monari; S Kenno; E Pericolini; E Gabrielli; D Pietrella; S Perito; F Bistoni; T R Kozel; A Vecchiarelli
Journal:  Infect Immun       Date:  2012-10-22       Impact factor: 3.441

7.  Therapy of experimental pseudomonas infections with a nonreplicating genetically modified phage.

Authors:  Steven Hagens; André Habel; Uwe von Ahsen; Alexander von Gabain; Udo Bläsi
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

8.  The novel human β-defensin 114 regulates lipopolysaccharide (LPS)-mediated inflammation and protects sperm from motility loss.

Authors:  Heguo Yu; Jing Dong; Yihua Gu; Haiyan Liu; Aijie Xin; Huijuan Shi; Fei Sun; Yonglian Zhang; Donghai Lin; Hua Diao
Journal:  J Biol Chem       Date:  2013-03-12       Impact factor: 5.157

9.  Antibiotic-mediated release of tumour necrosis factor alpha and norharman in patients with hospital-acquired pneumonia and septic encephalopathy.

Authors:  Verena Eggers; Katja Fügener; Ortrud Vargas Hein; Hans Rommelspacher; Melvyn P Heyes; Wolfgang J Kox; Claudia D Spies
Journal:  Intensive Care Med       Date:  2004-04-27       Impact factor: 17.440

10.  Pharmacodynamic evaluation of the neutralization of endotoxin by PMX622 in mice.

Authors:  Philip Lake; Jeffrey DeLeo; Franklin Cerasoli; Lennart Logdberg; Marla Weetall; Dean Handley
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.